Groups Treatment/Dose (mg/mL) Liver Kidney Heart TBARs mM/100g. tissue HP mM/100g. tissue TBARs mM/100g. tissue HP mM/100g. tissue TBARs mM/100g. tissue HP mM/100g. tissue Normal Control 0.67 ± 0.029 48.70 ± 2.97 0.46 ± 0.051 29.65 ± 3.44 0.52 ± 0.042 36.18 ± 6.05 Control + CAMBA (25mg/kg) 0.62 ± 0.013 34.08 ± 4.11 0.40 ± 0.048 28.16 ± 3.62 0.50 ± 0.036 34.28 ± 4.11 Control + CAMBA (50mg/kg) 0.60 ± 0.019 25.69 ± 6.04 0.39 ± 0.062 25.93 ± 4.07 0.44 ± 0.092 30.42 ± 5.00 Diabetic Control 1.36 ± 0.028** 76.28 ± 5.53** 0.89 ± 0.076** 64.33 ± 5.16** 0.84 ± 0.045** 74.16 ± 6.03** Diabetic + CAMBA (25mg/kg) 0.67 ± 0.017** 42.55 ± 2.39** 0.50 ± 0.034** 34.28 ± 4.05** 0.59 ± 0.080** 34.48 ± 2.76** Diabetic +CAMBA (50mg/kg) 0.60 ± 0.035** 41.49 ± 3.27** 0.44 ± 0.047** 28.54 ± 3.70** 0.54 ± 0.045** 31.00 ± 2.98** Diabetic +Glibenclamide(5mg/kg) 0.63 ± 0.091** 46.58 ± 4.74** 0.55 ± 0.061** 32.53 ± 5.58** 0.53 ± 0.027** 39.07 ± 6.15** Values represent the mean ± SE (n=8). Diabetic control rats were compared with normal control rats. Experimental groups were compared with the diabetic control rats • **Significantly different from control group at p< 0.01

Table 5: Effect of CAMBA on liver, kidney and heart TBARs and HP in control and experimental groups of rats.